Lilly’s Zepbound Plus Taltz Boosts Arthritis Relief, Weight Loss in Late-Stage Trial

Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms

Data show that a combination treatment, including the therapy Taltz, was more effective than older therapy alone.

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight...

Lilly’s Zepbound Plus Arthritis Drug Taltz Eases Joint Pain

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater improvement in tender and swollen joints compared to those on Taltz alone, a new study found.

Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

New York, Jan 8, 2026, 18:23 EST — After-hours Shares of Eli Lilly fell 2.1% on Thursday, trading between $1,070.16 and $1,133.06, and were last at $1,085.19 in after-hours activity after the drugmaker reported late-stage data on a Zepbound-Taltz combination in psoriatic arthritis. Lilly said 31.7% of patients on the combo met a dual goal — at least 50% lower disease activity and at least 10% weight loss after 36 weeks — compared with 0.8% on Ta…

Eli Lilly Trial Shows Superior Outcomes with Ixekizumab and Tirzepatide in Patients with PsA and Obesity

Results from the TOGETHER-PsA trial reveal that combining ixekizumab and tirzepatide significantly improves outcomes for psoriatic arthritis patients with obesity.